Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen and Advaxis announce cancer immunotherapy collaboration

Amgen and Advaxis announce cancer immunotherapy collaboration

4th August 2016

Amgen has partnered with Advaxis to develop a new immunotherapy for the treatment for cancer.

The global agreement will see the companies work together on the development and commercialisation of Advaxis' ADXS-NEO, a novel preclinical treatment designed to activate the immune system to respond against unique mutations contained individual tumour types.

Amgen's development expertise in immuno-oncology will be leveraged alongside Advaxis' MINE (My Immunotherapy Neo-Epitopes) programme, which is designed to provide a customised approach to cancer treatment.

Under the terms of the deal,Amgen will receive exclusive worldwide rights to develop and commercialise ADXS-NEO, and will make an upfront payment to Advaxis of $40 million (30.01 million pounds). It will also purchase $25 million of Advaxis common stock and may need to pay out up to $475 million in development, regulatory and sales milestone payments.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "Amgen's collaboration with Advaxis leverages and enhances our development and commercialisation expertise in novel immuno-oncology treatments."ADNFCR-8000103-ID-801823114-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.